Meditor Group Ltd increased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 39.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 5,800,000 shares of the biopharmaceutical company’s stock after buying an additional 1,654,100 shares during the period. Celldex Therapeutics comprises about 2.2% of Meditor Group Ltd’s holdings, making the stock its 8th largest position. Meditor Group Ltd owned about 4.64% of Celldex Therapeutics worth $14,326,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 6,000 shares during the last quarter. Tudor Investment Corp Et Al boosted its stake in shares of Celldex Therapeutics by 256.6% in the fourth quarter. Tudor Investment Corp Et Al now owns 47,806 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 34,400 shares during the last quarter. Hikari Power Ltd acquired a new stake in shares of Celldex Therapeutics during the first quarter worth approximately $181,000. American International Group Inc. boosted its stake in shares of Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 3,880 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 1,409 shares during the last quarter. Hedge funds and other institutional investors own 65.85% of the company’s stock.
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 6.0935% during midday trading on Thursday, reaching $2.6099. 2,129,356 shares of the company’s stock were exchanged. The stock’s market cap is $326.51 million. The stock’s 50 day moving average is $2.44 and its 200-day moving average is $3.05. Celldex Therapeutics, Inc. has a 12-month low of $2.20 and a 12-month high of $5.02.
Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). The firm had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.57 million. Celldex Therapeutics had a negative return on equity of 53.10% and a negative net margin of 1,825.82%. On average, equities analysts expect that Celldex Therapeutics, Inc. will post ($1.10) EPS for the current year.
WARNING: This article was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2017/08/03/celldex-therapeutics-inc-nasdaqcldx-shares-bought-by-meditor-group-ltd-updated.html.
Several research firms have issued reports on CLDX. BidaskClub cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Cowen and Company reissued a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, June 6th. Zacks Investment Research lowered shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a report on Monday, July 17th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Celldex Therapeutics in a report on Tuesday. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $3.50 price target (down previously from $4.00) on shares of Celldex Therapeutics in a report on Thursday, May 11th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Celldex Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $7.32.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
